Related Experiment Videos
Radiosensitivity testing of human primary brain tumor specimens.
M J Allalunis-Turner1, G M Barron, R S Day
1Cross Cancer Institute, Edmonton, Alberta, Canada.
International Journal of Radiation Oncology, Biology, Physics
|January 1, 1992
Summary
This study assessed the radiosensitivity of glial brain tumors. Results indicate that inherent tumor cell radiosensitivity is not the primary factor determining patient response to radiotherapy.
Area of Science:
- Oncology
- Radiation Oncology
- Cell Biology
Background:
- Glioblastoma and other primary brain tumors are aggressive malignancies.
- Radiotherapy is a cornerstone treatment, but outcomes vary significantly among patients.
- Understanding the intrinsic radiosensitivity of tumor cells is crucial for predicting treatment response.
Purpose of the Study:
- To determine the inherent radiosensitivity of early passage cells from primary brain tumors of glial origin.
- To investigate correlations between radiosensitivity, tumor cell plating efficiency, and intracellular glutathione levels.
- To compare radiosensitivity between nitrosourea-resistant/Mer+ and nitrosourea-sensitive/Mer- tumor cells.
Main Methods:
- Utilized a clonogenic assay system to assess cell survival after irradiation.
- Quantified surviving fraction at 2 Gy for 22 patient-derived tumor cell lines.
- Measured intracellular glutathione levels and plating efficiency.
- Phenotyped cells for nitrosourea resistance and Mer expression.
Main Results:
- The mean surviving fraction at 2 Gy was 0.37 +/- 0.22, with a wide range (0.02-0.87).
- No significant correlation was found between inherent radiosensitivity and tumor cell plating efficiency or intracellular glutathione.
- No significant difference in radiosensitivity was observed between nitrosourea-resistant/Mer+ and nitrosourea-sensitive/Mer- tumor cells.
Conclusions:
- Inherent radiosensitivity of primary brain tumor cells shows considerable variability.
- Intracellular glutathione levels and plating efficiency do not correlate with radiosensitivity in these tumors.
- Clinical outcomes suggest that patient factors like performance status and age are more critical than intrinsic tumor radiosensitivity for radiotherapy response.